Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase

Pharmacogenetics and Genomics

Volumn 20, Issue 10, 2010, Pages 611-618

  Agrawal, Vishal ^a   Choi, Ji Ha ^b,c   Giacomini, Kathleen M ^b   Miller, Walter L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Ewha Womans University School of Medicine   (South Korea)

Author keywords

cytochrome P450; drug metabolism; electron transfer; enzymology; pharmacogenetics; proteinprotein interaction

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 REDUCTASE; ERYTHROMYCIN; MIDAZOLAM; QUINIDINE; TESTOSTERONE;

ARTICLE; CATALYSIS; ENZYME ACTIVITY; ENZYME CONFORMATION; ENZYME SPECIFICITY; GENETIC VARIABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

EID: 77957220642     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833e0cb5     Document Type: Article

References (52)

1. Ono T, Bloch K. Solubilization and partial characterization of rat liver squalene epoxidase. J Biol Chem 1975; 250:1571-1579.
2. Nishino H, Ishibashi T. Evidence for requirement of NADPH-cytochrome P450 oxidoreductase in the microsomal NADPH-sterol delta7-reductase system. Arch Biochem Biophys 2000; 374:293-298. (Pubitemid 30120265)
3. Wilks A, Black SM, Miller WL, Ortiz de Montellano PR. Expression and characterization of truncated human heme oxygenase (hHO-1) and a fusion protein of hHO-1 with human cytochrome P450 reductase. Biochemistry 1995; 34:4421-4427.
4. Vermilion JL, Ballou DP, Massey V, Coon MJ. Separate roles for FMN and FAD in catalysis by liver microsomal NADPH-cytochrome P-450 reductase. J Biol Chem 1981; 256:266-277.
5. Wang M, Roberts DL, Paschke R, Shea TM, Masters BS, Kim JJ. Threedimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes. Proc Natl Acad Sci U S A 1997; 94:8411-8416. (Pubitemid 27335052)
6. Ellis J, Gutierrez A, Barsukov IL, Huang WC, Grossmann JG, Roberts GC. Domain motion in cytochrome P450 reductase: conformational equilibria revealed by NMR and small-angle x-ray scattering. J Biol Chem 2009; 284:36628-36637.
7. Shen AL, OLeary KA, Kasper CB. Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J Biol Chem 2002; 277:6536-6541.
8. Otto DM, Henderson CJ, Carrie D, Davey M, Gundersen TE, Blomhoff R, et al. Identification of novel roles of the cytochrome p450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis. Mol Cell Biol 2003; 23:6103-6116. (Pubitemid 37013089)
9. Henderson CJ, Otto DM, Carrie D, Magnuson MA, McLaren AW, Rosewell I, et al. Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase. J Biol Chem 2003; 278:13480-13486. (Pubitemid 36800122)
10. Gu J,Weng Y, Zhang QY, Cui H, Behr M,Wu L, et al. Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase. J Biol Chem 2003; 278:25895-25901. (Pubitemid 36835351)
11. Fluck CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF, et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004; 36:228-230. (Pubitemid 38282745)
12. ArltW,Walker EA, Draper N, Ivison HE, Ride JP, Hammer F, et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. The Lancet 2004; 363:2128-2135. (Pubitemid 38844154)
13. Adachi M, Asakura Y, Matsuo M, Yamamoto T, Hanaki K, Arlt W. POR R457H is a global founder mutation causing Antley-Bixler syndrome with autosomal recessive trait. Am J Med Genet Part A 2006; 140A:633-635. (Pubitemid 43376302)
14. Sahakitrungruang T, Huang N, Tee MK, Agrawal V, Russell WE, Crock P, et al. Clinical, genetic, and enzymatic characterization of P450 oxidoreductase deficiency in four patients. J Clin Endocrinol Metab 2009; 94:4992-5000.
15. Homma K, Hasegawa T, Nagai T, Adachi M, Horikawa R, Fujiwara I, et al. Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. J Clin Endocrinol Metab 2006; 91:2643-2649. (Pubitemid 44024631)
16. Fukami M, Nishimura G, Homma K, Nagai T, Hanaki K, Uematsu A, et al. Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients. J Clin Endocrinol Metab 2009; 94:1723-1731.
17. Huang N, Agrawal V, Giacomini KM, Miller WL. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci U S A 2008; 105:1733-1738. (Pubitemid 351346583)
18. Hart SN, Wang S, Nakarnoto K, Wesselman C, Li Y, Zhong XB. Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism. Pharmacogenet Genomics 2008; 18:11-24. (Pubitemid 351161645)
19. Huang N, Pandey AV, Agrawal V, Reardon W, Lapunzina PD, Mowat D, et al. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am J Hum Genet 2005; 76:729-749. (Pubitemid 40563096)
20. Sim SC, Miller WL, Zhong XB, Arlt W, Ogata T, Ding X, et al. Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. Pharmacogenet Genomics 2009; 19:565-566.
21. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004; 25:193-200. (Pubitemid 38519910)
22. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487-491.
23. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, et al. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 2004; 305:683-686. (Pubitemid 39006760)
24. Ekroos M, Sjogren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci U S A 2006; 103:13682-13687. (Pubitemid 44413967)
25. Schellens JHM, Soons PA, Breimer DD. Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem Pharmacol 1988; 37:2507-2510.
26. Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, Endrenyi L, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10:373-388. (Pubitemid 30433571)
27. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 2009; 48:689-723.
28. Hart SN, Zhong XB. P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 2008; 4:439-452. (Pubitemid 351728517)
29. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116:496-526. (Pubitemid 350116943)
30. Agrawal V, Huang N, Miller WL. Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet Genomics 2008; 18:569-576.
31. Gillam EMJ, Baba T, Kim BR, Ohmori S, Guengerich FP. Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch Biochem Biophys 1993; 305:123-131. (Pubitemid 23242002)
32. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964; 239:2370-2378.
33. Miwa GT, Lu AY. The association of cytochrome P-450 and NADPHcytochrome P-450 reductase in phospholipid membranes. Arch Biochem Biophys 1984; 234:161-166.
34. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 1988; 263:424-436.
35. Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, et al. Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states. Clin Pharmacol Ther 2004; 76:104-112.
36. Guengerich FP, Muller-Enoch D, Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 1986; 30:287-295. (Pubitemid 16018853)
37. Smalley J, Kadiyala P, Xin B, Balimane P, Olah T. Development of an on-line extraction turbulent flow chromatography tandem mass spectrometry method for cassette analysis of Caco-2 cell based bi-directional assay samples. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 830:270-277. (Pubitemid 43075462)
38. Gomes LG, Huang N, Agrawal V, Mendonca BB, Bachega TA, Miller WL. The common P450 oxidoreductase variant A503 V is not a modifier gene for 21-hydroxylase deficiency. J Clin Endocrinol Metab 2008; 93:2913-2916. (Pubitemid 352008571)
39. Dierks EA, Davis SC, Ortiz de Montellano PR. Glu-320 and Asp-323 are determinants of the CYP4A1 hydroxylation regiospecificity and resistance to inactivation by 1-aminobenzotriazole. Biochemistry 1998; 37:1839-1847.
40. Nicolo C, Fluck CE, Mullis PE, Pandey AV. Restoration of mutant cytochrome P450 reductase activity by external flavin. Mol Cell Endocrinol 2010; 321:245-252.
41. Pandey AV, Kempna P, Hofer G, Mullis PE, Fluck CE. Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase. Mol Endocrinol 2007; 21:2579-2595. (Pubitemid 47529367)
42. Oneda B, Crettol S, Sirot EJ, Bochud M, Ansermot N, Eap CB. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics 2009; 19:877-883.
43. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 2004; 279:38091-38094.
44. Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007; 6:904-916. (Pubitemid 350042398)
45. Dresser MJ, Leabman MK, Giacomini KM. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci 2001; 90:397-421.
46. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117:1422-1431. (Pubitemid 46718430)
47. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348:529-537. (Pubitemid 36159889)
48. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med 2003; 348:538-549. (Pubitemid 36159890)
49. Fluck CE, Mullis PE, Pandey AV. Modeling of human P450 oxidoreductase structure by in silico mutagenesis and MD simulation. Mol Cell Endocrinol 2009; 313:17-22.
50. Hubbard PA, Shen AL, Paschke R, Kasper CB, Kim JJ. NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer. J Biol Chem 2001; 276:29163-29170. (Pubitemid 37452005)
51. Marohnic CC, Panda SP, Martasek P, Masters BS. Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase. J Biol Chem 2006; 281:35975-35982. (Pubitemid 46041329)
52. Marohnic CC, Panda SP, McCammon K, Rueff J, Masters BS, Kranendonk M. Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect. Drug Metab Dispos 2010; 38:332-340.